Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
Tianjin Medical University, Tianjin, China.
Clin Chim Acta. 2018 Mar;478:166-170. doi: 10.1016/j.cca.2017.12.041. Epub 2017 Dec 27.
To observe the change of the inflammatory factor Galectin-3 in patients with coronary heart disease, and the correlation between Galectin-3 and the severity of the disease. To observe changes of Galectin-3 in patients with atrial fibrillation (AF) before and after radiofrequency ablation, and the changes of Galectin-3 before and after an interim treatment with a high dose of atorvastatin on patients with acute myocardial infarction(AMI).
Patients with coronary heart disease and atrial fibrillation having normal heart function were selected, among them, the patients with AMI were given a short term treatment of 80mg atorvastatin before PCI, and patients with atrial fibrillation underwent radiofrequency catheter ablation. ELISA technique was equipped to observe the Galectin-3 changes in patients with coronary heart disease and that of patients with AF before and after radiofrequency ablation.
Galectin-3 level of the AMI group was higher than that of the unstable angina pectoris (UAP) group, and its levels were higher than that of the stable angina pectoris (SAP) group, the differences were statistically significant among both groups (P<0.05); Galectin-3 level of multivessel coronary disease group was higher than that of single vessel group, in which a statistically significant difference was noted (P<0.05); There was no statistically significant difference associated in the drop of Galectin-3 levels in patients with AMI after PCI (P>0.05); Galectin-3 of patients with AF decreased after RFCA, but no statistical significance noted (P>0.05); Galectin-3 was negatively correlated with the LVEF value(r=-0.405, P<0.05).
Galectin-3 belongs to a class of inflammatory mediators that is associated with the degree of myocardial inflammation and fibrosis. It is related to the severity of myocardial ischemia and is negatively correlated with the cardiac ejection fraction.
观察冠心病患者炎症因子半乳糖凝集素-3（Galectin-3）的变化，及其与疾病严重程度的相关性。观察心房颤动（AF）患者射频消融前后Galectin-3 的变化，以及急性心肌梗死（AMI）患者大剂量阿托伐他汀中间治疗前后 Galectin-3 的变化。
选取心功能正常的冠心病合并心房颤动患者，其中 AMI 患者行 PCI 前短期给予 80mg 阿托伐他汀治疗，心房颤动患者行射频导管消融术。采用 ELISA 技术观察冠心病患者及射频消融前后 AF 患者 Galectin-3 的变化。
AMI 组 Galectin-3 水平高于不稳定型心绞痛（UAP）组，高于稳定型心绞痛（SAP）组，差异有统计学意义（P<0.05）；多支血管病变组 Galectin-3 水平高于单支血管病变组，差异有统计学意义（P<0.05）；AMI 患者 PCI 后 Galectin-3 水平下降差异无统计学意义（P>0.05）；AF 患者射频消融后 Galectin-3 降低，但差异无统计学意义（P>0.05）；Galectin-3 与 LVEF 值呈负相关（r=-0.405，P<0.05）。
Galectin-3 属于炎症介质的一种，与心肌炎症和纤维化程度有关，与心肌缺血严重程度相关，与左心室射血分数呈负相关。
